MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463823 | Name: MPP iodide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MPP iodide is an inhibitor of mitochondrial complex I (CI) and complex II (CII).

Chemical Structure

MPP iodide
MPP iodide
CAS#36913-39-0

Theoretical Analysis

MedKoo Cat#: 463823

Name: MPP iodide

CAS#: 36913-39-0

Chemical Formula: C12H12IN

Exact Mass: 297.0014

Molecular Weight: 297.14

Elemental Analysis: C, 48.51; H, 4.07; I, 42.71; N, 4.71

Price and Availability

Size Price Availability Quantity
100mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MPP+ iodide; Cyperquat iodide; MPP iodide;
IUPAC/Chemical Name
1-methyl-4-phenylpyridin-1-ium iodide
InChi Key
RFDFRDXIIKROAI-UHFFFAOYSA-M
InChi Code
InChI=1S/C12H12N.HI/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11;/h2-10H,1H3;1H/q+1;/p-1
SMILES Code
C[N+]1=CC=C(C2=CC=CC=C2)C=C1.[I-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 297.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Anjaneyulu J, R V, Godbole A. Differential effect of Ayurvedic nootropics on C. elegans models of Parkinson's disease. J Ayurveda Integr Med. 2020 Oct- Dec;11(4):440-447. doi: 10.1016/j.jaim.2020.07.006. Epub 2020 Sep 22. PMID: 32978047; PMCID: PMC7772502. 2: Nho JH, Park MJ, Park HJ, Lee JH, Choi JH, Oh SJ, Lee YJ, Yu YB, Kim HS, Kim DI, Choi WS. Protein arginine methyltransferase-1 stimulates dopaminergic neuronal cell death in a Parkinson's disease model. Biochem Biophys Res Commun. 2020 Sep 17;530(2):389-395. doi: 10.1016/j.bbrc.2020.05.016. Epub 2020 Jun 10. PMID: 32532423. 3: Wu TT, Liu T, Li X, Chen YJ, Chen TJ, Zhu XY, Chen JL, Li Q, Liu Y, Feng Y, Wu YC. TET2-mediated Cdkn2A DNA hydroxymethylation in midbrain dopaminergic neuron injury of Parkinson's disease. Hum Mol Genet. 2020 May 28;29(8):1239-1252. doi: 10.1093/hmg/ddaa022. PMID: 32037456. 4: Zhong J, Dong W, Qin Y, Xie J, Xiao J, Xu J, Wang H. Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease. Br J Pharmacol. 2020 May;177(10):2333-2350. doi: 10.1111/bph.14983. Epub 2020 Feb 26. PMID: 31972868; PMCID: PMC7174887. 5: Guo C, Zhu J, Wang J, Duan J, Ma S, Yin Y, Quan W, Zhang W, Guan Y, Ding Y, Wen A, Zhang Y. Neuroprotective effects of protocatechuic aldehyde through PLK2/p-GSK3β/Nrf2 signaling pathway in both in vivo and in vitro models of Parkinson's disease. Aging (Albany NY). 2019 Nov 6;11(21):9424-9441. doi: 10.18632/aging.102394. Epub 2019 Nov 6. PMID: 31697645; PMCID: PMC6874433. 6: Limboonreung T, Tuchinda P, Chongthammakun S. Chrysoeriol mediates mitochondrial protection via PI3K/Akt pathway in MPP+ treated SH-SY5Y cells. Neurosci Lett. 2020 Jan 1;714:134545. doi: 10.1016/j.neulet.2019.134545. Epub 2019 Oct 14. PMID: 31622648. 7: Chen Y, Wu T, Li H, Li X, Li Q, Zhu X, Yu M, Kuo SH, Huang F, Wu YC. Dl-3-n-Butylphthalide Exerts Dopaminergic Neuroprotection Through Inhibition of Neuroinflammation. Front Aging Neurosci. 2019 Feb 28;11:44. doi: 10.3389/fnagi.2019.00044. PMID: 30873019; PMCID: PMC6403182. 8: Sharma N, Rao SP, Kalivendi SV. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Free Radic Biol Med. 2019 May 1;135:28-37. doi: 10.1016/j.freeradbiomed.2019.02.014. Epub 2019 Feb 20. PMID: 30796974. 9: Peng S, Wang C, Ma J, Jiang K, Jiang Y, Gu X, Sun C. Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis in Parkinson's disease models both in vitro and in vivo. Br J Pharmacol. 2018 Feb;175(4):631-643. doi: 10.1111/bph.14110. Epub 2018 Jan 6. PMID: 29181847; PMCID: PMC5786457.

View History

Latrunculin A

Latrunculin A

BRD73842

BRD73842

NPD2639

NPD2639

SB1495

SB1495

TCMDC-125457

TCMDC-125457

BRD4 inhibitor 9a

BRD4 inhibitor 9a